Form 4: Cabaletta Bio CBO Granted Stock Options

Cabaletta Bio's Chief Business Officer, Arun Das, was granted 175,000 stock options with a $3.3 exercise price, vesting over several years.

Summary

• Arun Das, Chief Business Officer of Cabaletta Bio, Inc., was granted 175,000 stock options.
• The options have an exercise price of $3.3 per share.
• The transaction date for the grant was March 2, 2026.
• The options have an expiration date of March 1, 2036.
• Vesting for these options begins on March 1, 2027, with 25% of the shares vesting then, and the remainder vesting in twelve substantially equal quarterly installments thereafter.
• Vesting is contingent upon Arun Das's continued service to the company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard executive compensation event that positively aligns management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The stock option grant aligns the Chief Business Officer's long-term financial interests with those of the shareholders, incentivizing sustained performance.
• The multi-year vesting schedule promotes executive retention and commitment to the company's strategic goals.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders, though this is a standard aspect of equity compensation.

Risks

• The value of the stock options is subject to the future market price fluctuations of Cabaletta Bio's common stock.
• The vesting of the options is conditional on the reporting person's continued service, meaning the full benefit is not guaranteed if employment ceases.
• Potential dilution from the future exercise of these options could impact per-share earnings and ownership percentages.

Future Outlook

The vesting schedule for the stock options, extending over several years, indicates an expectation of continued service from the Chief Business Officer and aims to incentivize long-term performance and commitment to the company's success.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation in the biotechnology sector, designed to align executive incentives with shareholder value creation over the long term. This practice is widely adopted to attract, retain, and motivate key talent in a competitive industry.

Comparison to Industry Standards

• StockSavvy.ai observes that granting stock options with multi-year vesting schedules is a standard practice across the biotech industry, comparable to compensation structures seen at companies like Moderna or BioNTech for key executives, aiming to retain talent and incentivize performance.
• The exercise price of $3.3 would typically be set at or above the market price on the grant date, which is a common industry standard for incentive-based option grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to Arun Das, the Chief Business Officer, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from incentivized management focused on long-term value creation.
• Chief Business Officer: Receives significant long-term incentive compensation tied to the company's stock performance and continued service.

Next Steps

• Vesting of the stock options will occur according to the specified schedule, with the first 25% vesting on March 1, 2027.
• The Chief Business Officer may choose to exercise vested options at any point before the expiration date of March 1, 2036.

Key Dates

Keywords

Cabaletta Bio, CABA, Stock Options, Executive Compensation, Form 4, Insider Transaction, Arun Das, Chief Business Officer, Equity Grant